Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Maintains $93 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem has maintained a Hold rating on Biomarin Pharmaceutical with a price target of $93.
September 13, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity has reiterated its Hold rating for Biomarin Pharmaceutical, keeping the price target at $93. This suggests a neutral outlook on the stock.
The Hold rating and maintained price target of $93 by Canaccord Genuity indicates that the analyst does not expect significant short-term movement in Biomarin's stock price. This suggests a neutral impact on the stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100